Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  decitabine
Find trials that include:  Any drugs shown
Results 1-25 of 26 for your search:
Start Over
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Temporarily closed
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: E2906, NCI-2011-01992, CDR0000659585, ECOG-E2906, NCT01041703
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SGN33A-005, NCI-2016-00878, 2015-003482-28, NCT02785900
Dasatinib and Decitabine in Treating Patients with Accelerated or Blastic Phase Chronic Myelogenous Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0333, NCI-2012-00014, CA180357, NCT01498445
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B1371003, NCI-2012-01145, 2012-000684-24, NCT01546038
Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: 2652.00, NCI-2012-02224, 2652, FH#2652, NCT01729845
Combination Chemotherapy in Treating Patients with Recurrent Acute Myeloid Leukemia or Recurrent Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 64
Trial IDs: 2012-1064, NCI-2013-00548, NCT01794702
Decitabine, Vemurafenib, and Cobimetinib in Treating Patients with Stage IV Melanoma Who Have a BRAF Mutation
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201304715, NCI-2014-00838, ML28604, NCT01876641
Ruxolitinib Phosphate and Decitabine in Treating Patients with Myeloproliferative Neoplasms
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MPD-RC 109, NCI-2014-01264, GCO 13-1816, MPD-RC 107, NCT02076191
Omacetaxine Mepesuccinate and Decitabine in Treating Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and over
Trial IDs: 2013-0812, NCI-2014-02157, NCT02141477
Ruxolitinib Phosphate and Decitabine in Treating Patients with Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0344, NCI-2014-02299, NCT02257138
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: GS-US-339-1559, NCI-2016-00088, NCT02343939
Cladribine, Cytarabine, and Decitabine in Treating Patients with Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Phase: Phase II
Type: Treatment
Age: 60 and over
Trial IDs: 2011-0987, NCI-2012-00145, NCT01515527
Genomic Predictors of Decitabine Response in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201210102, NCI-2012-01576, NCT01687400
Decitabine and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 60
Trial IDs: HO11421, NCI-2012-01325, 2012-0217-CP002, 2012-0217-CP005, 2012-0217-CP012, NCT01707004
Different Schedules of Decitabine in Treating Older Patients with Previously Untreated Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 60 and over
Trial IDs: 2012-1017, NCI-2013-00463, NCT01786343
Chemotherapy in Treating Patients with Myelodysplastic Syndrome before Donor Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2661.00, NCI-2013-00538, 2661, NCT01812252
Selinexor (KPT-330) in Older Patients With Relapsed AML
Status: Active
Phase: Phase II
Type: Treatment
Age: 60 and over
Trial IDs: KCP-330-008, NCI-2014-00820, NCT02088541
Midostaurin and Decitabine in Treating Older Patients with Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: MC1483, NCI-2015-02107, NCT02634827
A Study to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 1315.2, NCI-2016-01034, 2015-002892-30, NCT02632721
Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and over
Trial IDs: M14-358, NCI-2014-01763, 2014-000687-18, NCT02203773
Pacritinib and Chemotherapy in Treating Patients with Acute Myeloid Leukemia and FLT3 Mutations
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-14169, NCI-2014-02436, NCT02323607
Decitabine and Cytarabine in Treating Older Patients with Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Status: Active
Phase: No phase specified
Type: Treatment
Age: 60 and over
Trial IDs: 9019, NCI-2014-00769, NCT02121418
Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Temporarily closed
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-14040, NCI-2014-01489, 2014C0146, NCT02316964
Start Over